UK markets closed
NIKKEI 225
38,471.20 -761.60 (-1.94%) HANG SENG
16,248.97 -351.49 (-2.12%) CRUDE OIL
85.13 -0.28 (-0.33%) GOLD FUTURES
2,401.20 +18.20 (+0.76%) DOW
37,871.76 +136.65 (+0.36%) Bitcoin GBP
50,614.36 -890.30 (-1.73%)
Organon & Co. (0A9W.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 07:01PM BST
| Previous close | 31.47 |
| Open | 31.60 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 31.38 - 31.60 |
| 52-week range | 18.68 - 32.36 |
| Volume | |
| Avg. volume | 1,369 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.79 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireOrganon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
JERSEY CITY, N.J., April 08, 2024--Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
Business WirePhase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
SHANGHAI, China & JERSEY CITY, N.J., April 08, 2024--Organon and Henlius announce that Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoint
Business WireOrganon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
JERSEY CITY, N.J., February 20, 2024--Organon Announces HADLIMA Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
© 2024 Yahoo. All rights reserved.